Advancing beyond traditional paraneoplastic evaluations
For physicians of patients with suspected axonal autoimmune neuropathies, understanding which laboratory test is best suited to their patients’ needs can be challenging. Overlapping clinical presentations, varying involvements, and onset discrepancies can paint a muddled picture of the cause of the illness.
Mayo Clinic Laboratories has been a trusted resource to reduce this confusion through our paraneoplastic autoantibody evaluation. While this test has a decades-long history, recent research has shown a better approach to laboratory testing for these disorders. Driven by expanding scientific knowledge about the role of antibodies in peripheral neuropathy, and powered by Mayo Clinic clinical and research expertise, our autoimmune axonal panel is an evolution from our previous approach, which focused more narrowly on evaluating only antibodies with paraneoplastic associations.
Using multiple testing methodologies to achieve heightened specificity for antibody detection, our targeted axonal panel only includes antibodies with clinical relevance. Results from the thoughtfully curated panel not only enable information about underlying disease etiology, but direct physicians to search for underlying cancer, assist in understanding the natural history of the disease, and clarify treatment regimens.
Which test should I order?
A Test in Focus
Divyanshu Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.
Learn more about ordering Mayo Clinic Laboratories’ autoimmune neuropathy testing evolution at your institution.
Learn more about Mayo Clinic Laboratories’ targeted approach to antibody testing for axonal autoimmune neuropathy.